Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) EBIT Margin (2016 - 2025)

Wave Life Sciences' EBIT Margin history spans 11 years, with the latest figure at 606.49% for Q2 2025.

  • For Q2 2025, EBIT Margin fell 42877.0% year-over-year to 606.49%; the TTM value through Dec 2025 reached 1205.01%, down 115736.0%, while the annual FY2025 figure was 504.09%, 40215.0% down from the prior year.
  • EBIT Margin reached 606.49% in Q2 2025 per WVE's latest filing, down from 542.82% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 11.51% in Q4 2024 to a low of 13648.77% in Q3 2022.
  • Average EBIT Margin over 5 years is 1910.08%, with a median of 205.98% recorded in 2023.
  • Peak YoY movement for EBIT Margin: plummeted -1362789bps in 2022, then soared 1365780bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 46.35% in 2021, then decreased by -16bps to 53.65% in 2022, then soared by 73bps to 14.57% in 2023, then surged by 179bps to 11.51% in 2024, then tumbled by -5368bps to 606.49% in 2025.
  • Per Business Quant, the three most recent readings for WVE's EBIT Margin are 606.49% (Q2 2025), 542.82% (Q1 2025), and 11.51% (Q4 2024).